GlassScriptPhysician profile
Gwen Webster
NPI 1902801814
$4,587.62
in general payments reported to CMS, 2019-2025
17 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.86 · 2020: $35.21 · 2021: $124 · 2022: $114 · 2023: $266 · 2024: $2,332 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,800 · Food and Beverage: $415 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,800.00 |
| Food and Beverage | $414.84 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $3,800.00 | 2024-2025 | Bovine Collagen |
| Pfizer INC. | $163.15 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $121.79 | 2022-2025 | |
| Abbvie INC. | $104.85 | 2020-2023 | Lo Loestrin Fe, Orilissa |
| Bayer Healthcare Pharmaceuticals INC. | $91.77 | 2019-2023 | |
| Millicent US INC | $68.81 | 2023-2024 | Intrarosa, Femring |
| Astellas Pharma US INC | $67.46 | 2023-2024 | Veozah |
| Exeltis, USA INC. | $28.26 | 2024-2025 | Slynd |
| Myovant Sciences INC. | $21.83 | 2021 | |
| Mylan Pharmaceuticals INC. | $20.33 | 2021 | |
| Evofem Biosciences, INC. | $18.09 | 2021 | |
| Organon LLC | $17.63 | 2024 | |
| Therapeuticsmd, INC. | $16.75 | 2019 | |
| Coopersurgical, INC. | $16.61 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.64 | 2024 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicem INC. | $14.65 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gwen Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.